Clinical Publications

• Holyoake A, O’Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008;14:742–9. [pdf available]
• O’Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012;188:741–7
• Kavalieris L, O’Sullivan PJ, Suttie JM, et al. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015;15:23. [pdf available]
• Breen V, Kasabov N, Kamat AM, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 2015;15:45. 
• Lotan Y, Raman JR, Shariat S, et al. The development and clinical validation of a high sensitivity urine biomarker test for the determination of recurrence in urothelial carcinoma patients. American Urological Association Annual Meeting 2016; San Diego, CA, USA. [abstract available]
• Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;1–8. [pdf available]
• Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426. [pdf available]
• Darling, D, Luxmanan, C, O’Sullivan, P, et al. Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma. Adv Ther 2017. doi:10.1007/s12325-017-0518-7. [pdf available]
• Lough T, Luo Q, Luxmanan C, et al. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis. BMC Urol 2018;18:18. [pdf available]
• Lough T, Luo Q, O'Sullivan P, et al. Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis. Oncol Ther 2018. [pdf available]
• Konety, B, Shore, N, Kader, AK, et al. Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy. Eur Urol 2019. Article In-Press [pdf available] >> Uro Today Journal Club review by Sia Daneshmand M.D., Associate Professor or Urology, Director of Urological Oncology & Director of Clinical Research at University of Southern California (USC): [video link]
• Georgieva, MV, Wheeler, SB, Erim, D, et al. Comparison of the Harms, Advantages, and Costs Associated With Alternative Guidelines for the Evaluation of Hematuria. JAMA Intern Med. 2019; 10.1001 [abstract available]
• Davidson, PJ, McGeoch, G, Shand, B. Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy. NZ Med J 2019; 132:1497. [pdf available]
• Koya M, Osborne S, Chemasle C, Porten S, Schuckman A, Kennedy-Smith A. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urology. 2020; 20:12. [pdf available]
• Davidson P, McGeoch G, Shand B. Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy. NZ Med J 2020. 133:1527 [pdf available]

To request printed versions of our publications, please contact: us.info@pacificedgedx.com

Last Updated: 23 Mar 2021 08:20 am